Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
S Vincent Rajkumar1, P Leif Bergsagel2, Shaji Kumar1
1Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.
Hematology/Oncology Clinics of North America
|December 29, 2023
Summary
Smoldering multiple myeloma (SMM) is a precursor to multiple myeloma. Identifying high-risk SMM patients allows for early intervention with therapies like lenalidomide to potentially halt disease progression.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Smoldering multiple myeloma (SMM) is an intermediate stage in plasma cell disorders.
- SMM is heterogeneous, with roughly 50% progressing to multiple myeloma (biologic malignancy) and 50% remaining as monoclonal gammopathy of undetermined significance (premalignancy).
Purpose of the Study:
- To identify patients with high-risk SMM, indicating likely malignant transformation.
- To establish criteria for early intervention in high-risk SMM.
Main Methods:
- Utilized specific prognostic factors to identify patients with high-risk SMM.
- Defined high-risk SMM as a stage where malignant transformation is probable.
Main Results:
- Established a method to identify patients with high-risk SMM using prognostic factors.
- Identified a subset of SMM patients with a high likelihood of malignant transformation.
Conclusions:
- Patients with newly diagnosed high-risk SMM are candidates for early intervention.
- Early intervention options include lenalidomide or lenalidomide plus dexamethasone for two years, or clinical trial enrollment.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.5K